BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Grafe LA, Eacret D, Luz S, Gotter AL, Renger JJ, Winrow CJ, Bhatnagar S. Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress. Neuroscience 2017;348:313-23. [PMID: 28257896 DOI: 10.1016/j.neuroscience.2017.02.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
2 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198:79-121. [PMID: 22813971 DOI: 10.1016/B978-0-444-59489-1.00007-0] [Cited by in Crossref: 140] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
3 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
4 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
5 Korabelnikova EA, Danilov AB, Danilov AB, Vorobyeva YD, Latysheva NV, Artemenko AR. Sleep Disorders and Headache: A Review of Correlation and Mutual Influence. Pain Ther 2020;9:411-25. [PMID: 32621175 DOI: 10.1007/s40122-020-00180-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Grandner MA, Perlis ML. Pharmacotherapy for Insomnia Disorder in Older Adults. JAMA Netw Open 2019;2:e1918214. [PMID: 31880788 DOI: 10.1001/jamanetworkopen.2019.18214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grafe LA, Bhatnagar S. Orexins and stress. Front Neuroendocrinol 2018;51:132-45. [PMID: 29932958 DOI: 10.1016/j.yfrne.2018.06.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
8 Merlo Pich E, Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci 2014;8:26. [PMID: 24592206 DOI: 10.3389/fnins.2014.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
9 Ong JJY, Wei DY, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 2018;78:411-37. [PMID: 29396834 DOI: 10.1007/s40265-018-0865-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
10 Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci 2012;6:78. [PMID: 23189046 DOI: 10.3389/fnbeh.2012.00078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
11 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
12 Schroeder AM, Colwell CS. How to fix a broken clock. Trends Pharmacol Sci 2013;34:605-19. [PMID: 24120229 DOI: 10.1016/j.tips.2013.09.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
13 Radke AK, Sneddon EA, Frasier RM, Hopf FW. Recent Perspectives on Sex Differences in Compulsion-Like and Binge Alcohol Drinking. Int J Mol Sci 2021;22:3788. [PMID: 33917517 DOI: 10.3390/ijms22073788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A. OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depress Anxiety 2015;32:671-83. [PMID: 26332431 DOI: 10.1002/da.22403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
15 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
16 Bigal ME, Hargreaves RJ. Why does sleep stop migraine? Curr Pain Headache Rep 2013;17:369. [PMID: 24037443 DOI: 10.1007/s11916-013-0369-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
17 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
18 Calva CB, Fayyaz H, Fadel JR. Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1). J Neurochem 2018;145:232-44. [PMID: 29250792 DOI: 10.1111/jnc.14279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Contoreggi C. Corticotropin releasing hormone and imaging, rethinking the stress axis. Nucl Med Biol 2015;42:323-39. [PMID: 25573209 DOI: 10.1016/j.nucmedbio.2014.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chieffi S, Messina G, Villano I, Messina A, Esposito M, Monda V, Valenzano A, Moscatelli F, Esposito T, Carotenuto M, Viggiano A, Cibelli G, Monda M. Exercise Influence on Hippocampal Function: Possible Involvement of Orexin-A. Front Physiol 2017;8:85. [PMID: 28261108 DOI: 10.3389/fphys.2017.00085] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
21 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
23 German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 2013;4:1224-7. [PMID: 24707347 DOI: 10.1021/ml400333a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
24 Zlebnik NE, Holtz NA, Lepak VC, Saykao AT, Zhang Y, Carroll ME. Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior. Drug Alcohol Depend 2021;224:108719. [PMID: 33940327 DOI: 10.1016/j.drugalcdep.2021.108719] [Reference Citation Analysis]